SNORA75: A Protein Targeted for Cancer and Angiogenesis (G654321)

Target Name: SNORA75

NCBI ID: G654321

SNORA75

Other Name(s): U23 | Small nucleolar RNA, H/ACA box 75 | small nucleolar RNA, H/ACA box 75 | SNORA75A

SNORA75: A Protein Targeted for Cancer and Angiogenesis

SNORA75 (U23) is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of protein synthesis. It has been shown to play a role in the development and progression of various diseases, including cancer. As a result, SNORA75 has become a focus of interest for researchers as a potential drug target or biomarker.

SNORA75 is a 75 amino acid long protein that is expressed in the ER and is composed of two distinct domains: an N-terminus and a C-terminus. The N-terminus of SNORA75 contains a putative transmembrane domain (TMD) that is involved in the formation of a protein-protein interaction network. The TMD is composed of a long amino acid sequence that is involved in the formation of a hydrophobic core, which is thought to play a role in the stability and localization of the protein.

The C-terminus of SNORA75 contains a protein-coding domain that is responsible for the function of the protein. This domain is composed of a series of well- conserved amino acid residues that are involved in the regulation of protein synthesis. Specifically, the C-terminus of SNORA75 contains a series of amino acids that are involved in the binding of small molecules to the protein. These amino acids are thought to play a role in the regulation of protein synthesis by allowing the protein to interact with small molecules in the environment.

SNORA75 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of SNORA75 are associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer that arises from the ducts that carry bicarbonate from the intestine to the pancreas. Additionally, studies have shown that SNORA75 is involved in the regulation of the angiogenesis, which is the process by which new blood vessels are formed. This is thought to contribute to the development of blood-borne diseases, such as heart disease and cancer.

As a result, SNORA75 has become a focus of interest for researchers as a potential drug target or biomarker. Researchers are interested in understanding the function of SNORA75 and how it contributes to the development and progression of disease. In addition, researchers are interested in developing small molecules that can interact with SNORA75 and inhibit its function. This may lead to the development of new treatments for various diseases.

In conclusion, SNORA75 is a protein that is expressed in the ER and is involved in the regulation of protein synthesis. It has been shown to play a role in the development and progression of various diseases, including cancer. As a result, SNORA75 has become a focus of interest for researchers as a potential drug target or biomarker. Further research is needed to understand the full function of SNORA75 and its potential as a therapeutic agent.

Protein Name: Small Nucleolar RNA, H/ACA Box 75

The "SNORA75 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA75 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets